Teva/Ivax acquisition closes
Teva completes $7.4 bil. acquisition of Ivax Jan. 26. The deal, announced in July 2005, makes Teva the world's largest generic pharmaceutical firm (1"The Pink Sheet" Aug. 1, 2005, p. 19). Teva said it "expects the acquisition to become accretive by the end of the first year." As part of FTC-ordered divestitures, to be completed by Feb. 5, Teva will sell 11 products to Par and four to Barr; all 15 products will be supplied by Teva until the companies can manufacturer the products independently...
You may also be interested in...
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.